For immediate release 19 January 2016
Evgen Pharma plc
("Evgen" or the "Company")
Director Share Purchases
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 18 January 2016, certain Directors purchased an aggregate of 136,000 ordinary shares of 0.25 pence each at a price of 22.5 pence per share. The Directors participating in the purchase and their interests in the share capital of the Company following the purchase are as follows:
Director
Number of Ordinary Shares pursuant to Directors' dealing
Holding following Directors' dealing
Percentage of Ordinary Shares following Directors' dealing
Barry Clare
40,000
940,108
1.3%
Stephen Franklin
56,000
1,375,200
1.9%
John Bradshaw
0.1%
Enquiries:
+44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
www.evgen.com
Northland Capital Partners Limited
+44 (0) 20 7382 1100
Matthew Johnson, Gerry Beaney,Margarita Mitropoulou (Corporate Finance)
John Howes (Corporate Broking)
Buchanan
Mark Court, Sophie Cowles, Stephanie Watson
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. For further information please visit www.evgen.com